NEW YORK (GenomeWeb) – LabCorp subsidiary Esoterix Genetic Laboratories is suing Qiagen in a US district court alleging that Qiagen breached a licensing agreement between the companies regarding EGFR genetic testing by offering it for commercial research and diagnostic purposes ahead of US Food a
Researchers from Johns Hopkins have identified a marker, Mig6, that in early studies has been able to predict longer survival among patients taking the EGFR tyrosine kinase inhibitors gefitinib (Astra Zeneca's Iressa) and erlotinib (Genenetech's Tarceva).
Originally published May 14.
Smoking, most people have come to accept, is a major cause of lung cancer. But each year in the US, up to 24,000 men and women who have never smoked still end up dying from the disease.
In the first quarter of this year, pharmacogenetically targeted cancer drugs Xalkori and Zelboraf had marked increases in revenues from the previous year's quarter.
